Interpace Diagnostics Group (IDXG) AI Stock Analysis

• Market Cap: $3.96M
• Dividend Yield: N/A
• Average Volume (3M): 13.95K
• Price to Earnings (P/E): 0.8
• Beta (1Y): 2.19
• Revenue Growth: 18.70%
• EPS Growth: 591.31%
• Country: US
• Employees: 111
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.06
• Shares Outstanding: 4,423,093
• 10 Day Avg. Volume: 10,660
• 30 Day Avg. Volume: 13,951
• PEG Ratio: 0.01
• Price to Book (P/B): -1.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.88
• Enterprise Value/Market Cap: 1.95
• Enterprise Value/Revenue: 0.04
• Enterprise Value/Gross Profit: 0.26
• Enterprise Value/Ebitda: 0.35
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Interpace Diagnostics Group's overall score is driven by strong financial performance with growth in revenue and profit margins, despite challenges with negative equity. Technical analysis reflects weak market momentum, while valuation suggests the stock may be undervalued. The absence of dividend yield limits income potential.

Interpace Diagnostics Group Business Overview & Revenue Model

Company Description

Interpace Diagnostics Group (IDXG) is a company operating in the healthcare sector, specializing in molecular diagnostics and pathology services. The company focuses on developing and commercializing molecular diagnostic tests that provide personalized information for the diagnosis and management of cancer and other diseases. Their core products include proprietary diagnostic assays that are designed to help healthcare providers assess the risk of cancer progression and tailor treatment plans accordingly.

How the Company Makes Money

Interpace Diagnostics Group makes money primarily through the sale of its molecular diagnostic tests and pathology services to healthcare providers, including hospitals, clinics, and physicians. The company generates revenue by processing and analyzing patient samples using its proprietary diagnostic assays. These tests are typically ordered by healthcare providers to aid in the diagnosis and management of cancer and other diseases. Interpace Diagnostics may also earn revenue through partnerships and collaborations with pharmaceutical companies, leveraging its diagnostic capabilities to support drug development and clinical trials. Additionally, reimbursement from insurance companies and government health programs for the diagnostic tests performed is a significant factor in its earnings.

Interpace Diagnostics Group Financial Statement Overview

Summary

Interpace Diagnostics Group shows strong revenue and profit margins, with improved cash flows. However, the balance sheet reveals ongoing financial challenges due to negative equity. Continued debt reduction and equity improvement are crucial for sustaining growth. Overall, the financials depict a company in recovery with notable risks.

Income Statement

Interpace Diagnostics Group has shown a significant improvement in its income statement metrics over the recent years. The gross profit margin for 2024 stands at 63.8%, reflecting efficient cost management. The net profit margin improved to 14.3%, indicating strong profitability. Revenue growth rate from 2023 to 2024 was 16.7%, showing solid growth momentum. The EBIT margin of 17.3% and EBITDA margin of 17.8% for 2024 suggest robust operating performance. Overall, the income statement reveals a positive growth trajectory and improved profitability.

Balance Sheet

The balance sheet shows ongoing financial challenges, with a negative stockholders' equity of -$2.2 million in 2024, indicating potential solvency issues. However, the company has reduced its debt levels significantly over time, with a debt-to-equity ratio improvement as total debt decreased to $1.18 million. Return on equity is not meaningful due to negative equity. The equity ratio remains negative, further emphasizing balance sheet weaknesses. Improvements in reducing debt and liabilities are positive steps, but negative equity poses risks.

Cash Flow

Cash flow analysis highlights a strong recovery in cash generation capabilities. The operating cash flow in 2024 was $4.65 million, significantly higher than in previous years. Free cash flow improved to $3.77 million, indicating better cash management. The free cash flow growth rate from 2023 to 2024 is 13.6%, showcasing effective capital allocation. The operating cash flow to net income ratio of 0.69 indicates efficient cash conversion. Overall, the cash flow statement reflects positive trends in liquidity and cash management.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
46.93M	40.21M	31.84M	41.31M	32.40M
	Gross Profit
29.93M	23.90M	18.23M	17.95M	10.72M
	EBIT
8.11M	2.80M	-3.84M	-11.74M	-26.55M
	EBITDA
8.36M	3.84M	-2.27M	-1.33M	-20.10M
	Net Income Common Stockholders
6.70M	802.00K	-5.87M	-14.75M	-26.20M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.46M	3.50M	4.83M	3.31M	2.77M
	Total Assets
14.79M	13.02M	15.98M	38.43M	45.68M
	Total Debt
5.86M	11.19M	16.09M	13.72M	4.74M
	Net Debt
4.39M	7.69M	11.26M	10.40M	1.97M
	Total Liabilities
17.01M	28.16M	79.05M	80.84M	74.76M
	Stockholders Equity
-2.22M	-15.14M	-63.07M	-42.42M	-29.08M
Cash Flow		Free Cash Flow
3.77M	3.32M	-8.01M	-9.07M	-16.15M
	Operating Cash Flow
4.65M	3.79M	-7.69M	-8.72M	-14.58M
	Investing Cash Flow
-876.00K	-87.00K	6.21M	-315.00K	-1.57M
	Financing Cash Flow
-5.81M	-5.03M	3.00M	8.98M	16.61M

Interpace Diagnostics Group Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXG, the sentiment is Neutral. The current price of 0.9 is above the 20-day moving average (MA) of 0.79, below the 50-day MA of 0.99, and below the 200-day MA of 1.71, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 52.58 is Neutral, neither overbought nor oversold. The STOCH value of 84.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IDXG.

Interpace Diagnostics Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDXG	61 Neutral	$3.96M	0.79	-42.17%	―	18.70%	591.31%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
KZIA	31 Underperform	$4.01M	―	-2639.52%	―	―	19.58%
OGEN	29 Underperform	$4.30M	―	-748.05%	―	-100.00%	76.55%
GLTO	29 Underperform	$3.81M	―	-91.32%	―	―	48.81%
ALLR	28 Underperform	$15.68M	―	-383.73%	―	―	99.43%
CHEK	26 Underperform	$5.41M	―	-74.17%	―	―	―